SCHEMBL24359678

SCHEMBL24359678

CC(C)C(=O)NCCCCCCC(=O)Nc1nc(-c2ccccc2)cs1

nearest known ligand 0.72

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ HDAC1 Q13547 11/20 0.72
▸ HDAC2 Q92769 9/20 0.72
▸ HDAC6 Q9UBN7 9/20 0.72
▸ HDAC9 Q9UKV0 8/20 0.72
▸ HDAC3 O15379 8/20 0.72
▸ HDAC10 Q969S8 7/20 0.72
▸ HDAC8 Q9BY41 7/20 0.72
▸ HDAC4 P56524 6/20 0.72
▸ HDAC7 Q8WUI4 6/20 0.72
▸ HDAC11 Q96DB2 6/20 0.72
▸ HDAC5 Q9UQL6 6/20 0.72
▸ PARP1 P09874 1/20 0.56
▸ MAPT P10636 1/20 0.56
▸ ELOVL1 Q9BW60 1/20 0.55
▸ NPC1 O15118 1/20 0.54
▸ CASP3 P42574 1/20 0.54
▸ RAB9A P51151 1/20 0.54
▸ SENP7 Q9BQF6 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29516444 1.00 HDAC1 (0.72) HDAC1HDAC2HDAC6HDAC9HDAC3
SCHEMBL24359604 0.91 HDAC1 (0.61) HDAC1HDAC2HDAC6HDAC9HDAC3
SCHEMBL24359341 0.88 HDAC1 (0.77) HDAC1HDAC2HDAC6HDAC9HDAC3
SCHEMBL24359607 0.87 HDAC1 (0.71) HDAC1HDAC2HDAC6HDAC9HDAC3
SCHEMBL24359677 0.87 HDAC1 (0.78) HDAC1HDAC2HDAC6HDAC9HDAC3
SCHEMBL24359606 0.85 HDAC1 (0.76) HDAC1HDAC2HDAC6HDAC9HDAC3
SCHEMBL24359691 0.85 HDAC1 (0.75) HDAC1HDAC2HDAC6HDAC9HDAC3
SCHEMBL27452867 0.83 HDAC1 (0.69) HDAC1HDAC2HDAC6HDAC9HDAC3
SCHEMBL30444296 0.83 HDAC1 (0.80) HDAC1HDAC2HDAC6HDAC9HDAC3
SCHEMBL11479812 0.83 HDAC1 (0.80) HDAC1HDAC2HDAC6HDAC9HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240327427-A1 NEW COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2024-10-03 — — US disclosed
WO-2022087456-A1 NEW COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2022-04-28 — — WO disclosed
WO-2022087456-A1 NEW COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2022-04-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240327427-A1 NEW COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE PSEN2, PSEN1, CHAT HDAC1 1254/4885HDAC2 1592/4885HDAC6 441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback